ATF5: A Protein Targeted for Cancer and Neurodegenerative Disorders

Target Name: ATF5

NCBI ID: G22809

ATF5

ATF5: A Protein Targeted for Cancer and Neurodegenerative Disorders

ATF5, also known as ATF5 variant 3, is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell growth and differentiation, and is involved in the development and maintenance of tissues such as muscle, bone, and skin.

Recent studies have identified ATF5 as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because of its involvement in several key cellular processes that are involved in the development and progression of these diseases.

One of the key functions of ATF5 is its role in cell growth and differentiation. ATF5 is a transcription factor that regulates the expression of genes that are involved in cell growth and development. It has been shown to play a key role in the development and maintenance of tissues such as muscle, bone, and skin.

ATF5 is also involved in the regulation of cell death and stress responses. It has been shown to play a key role in the stress response, and is involved in the regulation of cell death. This is important because disruptions in cell death and stress responses have been implicated in the development and progression of a variety of diseases.

In addition to its role in cell growth and differentiation, ATF5 is also involved in the regulation of cellular signaling pathways. It has been shown to play a key role in several signaling pathways, including the TGF-β pathway and the Wnt pathway. These signaling pathways are involved in the development and maintenance of tissues, and are important targets for drugs that are designed to treat diseases such as cancer and neurodegenerative disorders.

The identification of ATF5 as a potential drug target and biomarker has implications for the development of new treatments for a variety of diseases. By targeting ATF5 with drugs, researchers hope to be able to inhibit its activity and reduce the growth and progression of cancer cells, as well as the development and progression of neurodegenerative diseases.

In conclusion, ATF5 is a protein that is involved in several key cellular processes that are involved in the development and progression of diseases. Its potential as a drug target and biomarker makes it an attractive target for researchers to investigate. Further studies are needed to fully understand its role in the development and progression of diseases, and to identify effective treatments.

Protein Name: Activating Transcription Factor 5

Functions: Transcription factor that either stimulates or represses gene transcription through binding of different DNA regulatory elements such as cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), ATF5-specific response element (ARE) (consensus: 5'-C[CT]TCT[CT]CCTT[AT]-3') but also the amino acid response element (AARE), present in many viral and cellular promoters. Critically involved, often in a cell type-dependent manner, in cell survival, proliferation, and differentiation (PubMed:10373550, PubMed:15358120, PubMed:21212266, PubMed:20654631). Its transcriptional activity is enhanced by CCND3 and slightly inhibited by CDK4 (PubMed:15358120). Important regulator of the cerebral cortex formation, functions in cerebral cortical neuroprogenitor cells to maintain proliferation and to block differentiation into neurons. Must be down-regulated in order for such cells to exit the cycle and differentiate (By similarity). Participates in the pathways by which SHH promotes cerebellar granule neuron progenitor cells proliferation (By similarity). Critical for survival of mature olfactory sensory neurons (OSN), directs expression of OSN-specific genes (By similarity). May be involved in osteogenic differentiation (PubMed:22442021). Promotes cell proliferation and survival by inducing the expression of EGR1 sinergistically with ELK1. Once acetylated by EP300, binds to ARE sequences on target genes promoters, such as BCL2 and EGR1 (PubMed:21791614). Plays an anti-apoptotic role through the transcriptional regulation of BCL2, this function seems to be cell type-dependent (By similarity). Cooperates with NR1I3/CAR in the transcriptional activation of CYP2B6 in liver (PubMed:18332083). In hepatic cells, represses CRE-dependent transcription and inhibits proliferation by blocking at G2/M phase (PubMed:22528486, PubMed:18701499). May act as a negative regulator of IL1B transduction pathway in liver (PubMed:24379400). Upon IL1B stimulus, cooperates with NLK to activate the transactivation activity of C/EBP subfamily members (PubMed:25512613). Besides its function of transcription factor, acts as a cofactor of CEBPB to activate CEBPA and promote adipocyte differentiation (PubMed:24216764). Regulates centrosome dynamics in a cell-cycle- and centriole-age-dependent manner. Forms 9-foci symmetrical ring scaffold around the mother centriole to control centrosome function and the interaction between centrioles and pericentriolar material (PubMed:26213385)

The "ATF5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATF5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets